Seminar - Modelling disorders of the brain through patient-derived stem cells


McIntyre Medical Building Room 1034, 3655 promenade Sir William Osler, Montreal, QC, H3G 1Y6, CA

My research focus is on applying patient-derived stem cells towards the development of phenotypic discovery assays and 3D mini-brain models for both neurodegenerative and neurodevelopmental disorders. As associate director of the Early Drug Discovery Unit (EDDU) at the Montreal Neurological Institute (MNI), I oversee a team of over 35 research staff and students, committed to applying novel stem cell technology, combined with CRISPR genome editing, mini-brain models and new microfluidic technologies towards elucidating the underlying causes of these complex disorders. Combined with new approaches in the group towards building MultiOmics profiles on the patient-derived IPSC cells, the long-term strategy is to identify new personalized precision therapies that can be applied towards building clinical trials on a dish. For todays talk, I will discuss our 3D drug discovery pipeline, in which we focus on translating findings from 2D neurons, into 3D brain organoids, and ultimately into lead compounds. I will present work on how we generate these cells, the quality control process and also some of the new technologies we are developing in the group for working with 3D neuronal organoids.